TITLE

prostaglandin inhibitor

PUB. DATE
January 2005
SOURCE
Taber's Cyclopedic Medical Dictionary;2005, p1788
SOURCE TYPE
Book
DOC. TYPE
Reference Entry
ABSTRACT
A definition of the term "prostaglandin inhibitor" is presented. The term refers to inhibitors that inhibit the production of prostaglandins.Two major categories that inhibit prostaglandins are nonsteroidal and steroid anti-inflammatory agents.
ACCESSION #
21242423

 

Related Articles

  • NSAIDS. Dunkin, Mary Anne // Arthritis Today;Jul/Aug99, Vol. 13 Issue 4, p30 

    Provides information on nonsteroidal anti-inflammatory drugs (NSAID). How NSAID works; Beneficial functions of prostaglandins in the body; Possible side effects of NSAID. INSET: Easing NSAIDs' Stomach Damage.

  • Etodolac: An overview of a selective COX-2 inhibitor. Jones, Richard A. // Inflammopharmacology;1999, Vol. 7 Issue 3, p269 

    Evaluates the mechanism of action of Etodolac, a non-steroidal anti-inflammatory drug (NSAID) and a cyclo-oxygenase (COX) inhibitor shown to be effective in the treatment of rheumatoid and osteoarthritis. Side effects of NSAID on the gastrointestinal tract; COX-2 inhibition mechanism of...

  • Inhibition of COX in Ocular Tissues: An In Vitro Model to Identify Selective COX-2 Inhibitors. GarcĂ­a-Cabanes, C.; Palmero, M.; Bellot, J.L.; Castillo, M.; Orts, A. // Journal of Ocular Pharmacology & Therapeutics;Feb2001, Vol. 17 Issue 1, p67 

    The aim of this work was to study the regulation of LPS-stimulated PGE [sub 2] synthesis by traditional NSAIDs (piroxicam and diclofenac) and a selective COX-2 inhibitor (NS-398), in cultured bovine corneal endothelial cells and retinal pigmentary epithelial cells. The IC[sub 50] values of...

  • Clinical Potential of Cyclo-Oxygenase-2 Inhibitors. Oviedo, J.A.; Wolfe, M.M. // BioDrugs;2001, Vol. 15 Issue 9, p563 

    On the basis of their reduced potential to cause injury to the gastroduodenal mucosa, cyclo-oxygenase (COX)-2-selective inhibitors were developed and marketed as a safer alternative to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). This manuscript reviews the major steps leading to...

  • A strategy for evaluating the novel COX-2 inhibitors versus NSAIDs for arthritis. Motheral, Brenda R.; Bataoel, James R. // Formulary;Oct99, Vol. 34 Issue 10, p855 

    With the availability of the two new COX-2 inhibitors celecoxib and rofecoxib, drug decision makers must determine whether and how to cover them under the pharmacy benefit. The higher cost and improved side effect profile of the new COX-2 inhibitors must be weighed against the lower cost and...

  • Heterocyclic Compounds as Inflammation Inhibitors. Sondhi, Sham M.; Singhal, Nidhi; Johar, Monika; Reddy, B.S. Narayan; Lown, J. William // Current Medicinal Chemistry;May2002, Vol. 9 Issue 10, p1045 

    Clinical use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with significant toxicity particularly in the gastrointestinal tract and kidney. Various approaches such as formulation & co-administration (of agents to protect the stomach), chemical manipulation and synthesis of new...

  • NSAID Market Sees New API Opportunity. Boswell, Clay // Chemical Market Reporter;05/10/99, Vol. 255 Issue 19, pFR 16 

    Focuses on the opportunity offered by cyclooxygenase-2 (COX-2) specific inhibitor Celebrex, a chemical used to treat arthritis to chemical producers in the non-steroidal anti-inflammatory drugs (NSAID) market. Kinds of arthritis treated by NSAID; NSAID that dominate the market in 1998; Success...

  • Nitric Oxide, Aspirin-Triggered Lipoxins and NO-Aspirin in Gastric Protection. Wallace, John L. // Inflammation & Allergy - Drug Targets;Apr2006, Vol. 5 Issue 2, p133 

    The use of nonsteroidal anti-inflammatory drugs is associated with an incidence of severe gastrointestinal adverse events of 2-4%, the most common of which is bleeding. These events are largely attributable to the ability of these drugs to suppress prostaglandin and thromboxane synthesis....

  • Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders. Yermakova, A.; O'Banion, M.K. // Current Pharmaceutical Design;Nov2000, Vol. 6 Issue 17, p1755 

    Recognition of two isoforms of cyclooxygenase and reports that nonsteroidal anti-inflammatory drugs may be beneficial in devastating neurological conditions such as Alzheimer's disease have led to increased interest in cyclooxygenase function in the nervous system. In the present paper we review...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics